Christina W Chen1, Christiane Drechsler2, Pirianthini Suntharalingam3, S Ananth Karumanchi1, Christoph Wanner2, Anders H Berg4. 1. Division of Nephrology and Center for Vascular Biology Research, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. 2. Division of Nephrology, Department of Internal Medicine 1, University Hospital Würzburg and Comprehensive Heart Failure Center, Würzburg, Germany. 3. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. 4. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA. ahberg@bidmc.harvard.edu.
Abstract
BACKGROUND: Monitoring of glycemic control with hemoglobin A1c (A1c) in hemodialysis patients may be compromised by anemia and erythropoietin therapy. Glycated albumin (GA) is an alternative measure of glycemic control but is not commonly used because of insufficient evidence of association to clinical outcomes. We tested whether GA measurements were associated with mortality in hemodialysis patients with diabetes mellitus. METHODS: The German Diabetes and Dialysis Study (4D) investigated effects of atorvastatin on survival in 1255 patients with diabetes mellitus receiving hemodialysis. We measured GA during months 0, 6, and 12. Cox proportional hazards analysis was used to measure associations between GA and A1c and all-cause mortality. RESULTS: Patients with high baseline GA (fourth quartile) had a 42% higher 4-year mortality compared to those in the first quartile (HR 1.42; 95% CI, 1.09-1.85, P = 0.009). Repeated measurements of GA during year one also demonstrated that individuals in the top quartile for GA (analyzed as a time-varying covariate) had a 39% higher 4-year mortality (HR 1.39; 95% CI, 1.05-1.85, P = 0.022). The associations between high A1c and mortality using similar analyses were less consistent; mortality in individuals with baseline A1c values in the 3rd quartile was increased compared to 1st quartile (HR 1.36; 95% CI, 1.04-1.77, P = 0.023), but risk was not significantly increased in the 2nd or 4th quartiles, and there was a less consistent association between time-varying A1c values and mortality. CONCLUSIONS: High GA measurements are consistently associated with increased mortality in patients with diabetes mellitus on hemodialysis.
BACKGROUND: Monitoring of glycemic control with hemoglobin A1c (A1c) in hemodialysis patients may be compromised by anemia and erythropoietin therapy. Glycated albumin (GA) is an alternative measure of glycemic control but is not commonly used because of insufficient evidence of association to clinical outcomes. We tested whether GA measurements were associated with mortality in hemodialysis patients with diabetes mellitus. METHODS: The German Diabetes and Dialysis Study (4D) investigated effects of atorvastatin on survival in 1255 patients with diabetes mellitus receiving hemodialysis. We measured GA during months 0, 6, and 12. Cox proportional hazards analysis was used to measure associations between GA and A1c and all-cause mortality. RESULTS:Patients with high baseline GA (fourth quartile) had a 42% higher 4-year mortality compared to those in the first quartile (HR 1.42; 95% CI, 1.09-1.85, P = 0.009). Repeated measurements of GA during year one also demonstrated that individuals in the top quartile for GA (analyzed as a time-varying covariate) had a 39% higher 4-year mortality (HR 1.39; 95% CI, 1.05-1.85, P = 0.022). The associations between high A1c and mortality using similar analyses were less consistent; mortality in individuals with baseline A1c values in the 3rd quartile was increased compared to 1st quartile (HR 1.36; 95% CI, 1.04-1.77, P = 0.023), but risk was not significantly increased in the 2nd or 4th quartiles, and there was a less consistent association between time-varying A1c values and mortality. CONCLUSIONS: High GA measurements are consistently associated with increased mortality in patients with diabetes mellitus on hemodialysis.
Authors: Christopher J Hill; Alexander P Maxwell; Christopher R Cardwell; Barry I Freedman; Marcello Tonelli; Masanori Emoto; Masaaki Inaba; Yasuaki Hayashino; Shunichi Fukuhara; Tomonari Okada; Christiane Drechsler; Christoph Wanner; Anna Casula; Amanda I Adler; Claudia Lamina; Florian Kronenberg; Elani Streja; Kamyar Kalantar-Zadeh; Damian G Fogarty Journal: Am J Kidney Dis Date: 2013-08-16 Impact factor: 8.860
Authors: Elizabeth Selvin; Andreea M Rawlings; Pamela L Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh Journal: Circulation Date: 2015-05-28 Impact factor: 29.690
Authors: Dexiang Gao; Gary K Grunwald; John S Rumsfeld; Lynn Schooley; Todd MacKenzie; A Laurie W Shroyer Journal: Ann Thorac Surg Date: 2006-03 Impact factor: 4.330
Authors: Sidar Copur; Dimitrie Siriopol; Baris Afsar; Melis C Comert; Gizem Uzunkopru; Alan A Sag; Alberto Ortiz; Adrian Covic; Daniel H van Raalte; David Z Cherney; Peter Rossing; Mehmet Kanbay Journal: Acta Diabetol Date: 2020-08-30 Impact factor: 4.280
Authors: Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112